Skip to main content

Table 3 Results for newborn and child health systematic review protocols

From: Are child-centric aspects in newborn and child health systematic review and meta-analysis protocols and reports adequately reported?—two systematic reviews

  Proportion (%) of “Yes” responses for the total (no.) of reviews eligible for scoring
    Type of review Intervention/exposure group
Itema number Item Overall (N = 76) Cochrane (N = 50) Non-Cochrane (N = 26) p value Children only (N = 41) Children and adults (N = 24) Family and maternal (N = 11) p value
  Title
1) Identify the protocol as a systematic review, meta-analysis, or both for pediatric population as a focus of review, if applicable 72.4 (76) 88.5 (50) 64 (26) 0.015* 92.7 (41) 29.2 (24) 90.9 (11) p < 0.01*
  Support
5a) Indicate sources of financial or other support for the review
5b) Provide name for the review funder and/or sponsor
5c) Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
5d) For each included trial in a systematic review, indicate (a plan to include) the source of financial support (such as government, academia, or industry), if any, in the trial(s) 13.2 (76) 30.8 (50) 4 (26) 0.010* 19.5 (41) 8.3 (24) 0 (11) 0.178
  Introduction
  Rationale
6) Describe the rationale for the review in the context of what is already known
6a) In the contexts of the synthesized evidence in adults or other pediatric groups (non-targeted), explain the rationale for synthesizing evidence for the targeted pediatric age group(s). Provide hypotheses that relate to the targeted pediatric age group(s) 1.3 (76) 0 (50) 2 (26) 0.321 2.4 (41) 0 (24) 0 (11) 0.682
  Objectives
7) Provide an explicit statement of questions the review will address with reference to targeted pediatric age groups, interventions, comparisons, outcomes, and study design (PICOS). 0 (76) 0 (50) 0 (26) p > 0.999 0 (41) 0 (24) 0 (11) p > 0.999
  Methods
  Eligibility criteria
8) Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
8a) Justify the targeted pediatric age group(s) selected. 64.5 (76) 84.6 (50) 54 (26) p < 0.01* 78 (41) 45.8 (24) 54.5 (11) 0.022*
8b) Intervention: Justify the intervention for the targeted pediatric age group(s) addressing potential age-related differences in intervention effects 55.3 (76) 76.9 (50) 44 (26) p < 0.01* 61 (41) 37.5 (24) 72.7 (11) 0.075*
8c) Provide rationale for extrapolation or adaptation of adult intervention, if any 16.7 (18) 20 (13) 15.4 (5) 0.826 33.3 (6) 9.1 (11) 0 (1) 0.410
8d) Comparators: Explain the choice of comparator(s) and, if applicable, evidence for the active comparator and/or standard of care for targeted pediatric age group(s) 17.1 (76) 26.9 (50) 12 (26) 0.142 26.8 (41) 8.3 (24) 0 (11) 0.050
8e) Outcomes: List and define all the primary outcomes addressed for the targeted pediatric age group(s). List and define growth and development outcomes and adverse outcomes (events), if applicable 55.3 (76) 80.8 (50) 42 (26) p < 0.01* 78 (41) 12.5 (24) 63.6 (11) p < 0.01*
8f) Outcomes: Explain the clinical relevance of the selected outcomes (benefits and harms) for the targeted pediatric age group(s) 28.9 (76) 23.1 (50) 32 (26) 0.405 26.8 (41) 29.2 (24) 36.4 (11) 0.797
8g) Outcomes: Explain the validity, feasibility, and responsiveness of the outcome measures for the pre-targeted pediatric age group(s) 0 (76) 0 (50) 0 (26) p > 0.999 0 (41) 0 (24) 0 (11) p > 0.999
  Search strategy
10) Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
10a)  Describe the search strategy and terms (including database specific MeSH terms for pediatric population) used to address the targeted pediatric age group(s) 48.7 (76) 53.8 (50) 46 (26) 0.520 58.5 (41) 25 (24) 63.6 (11) 0.017*
  Data synthesis
15b) If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’sτ)
15b) For studies that included pediatrics and adults without a subgroup analysis of the pediatric population, describe how the data on targeted pediatric age group(s) were used in the analysis 0 (27) 0 (21) 0 (6) p > 0.999 0 (0) 0 (24) 0 (3) p > 0.999
  Additional analyses
15c) Describe methods of additional analyses (e.g., sensitivity or subgroup analyses for targeted pediatric age group(s), meta-regression), if done, indicating which were pre-specified 61 (59) 58.3 (35) 62.9 (24) 0.730 53.3 (30) 68.4 (19) 70 (10) 0.454
  1. *p-value correspondent to statistical significant at < 0.05
  2. aItem numbers are potential neonatal and child health modification (bold) and extension (a–g) items for PRISMA-P